2025年上半年表现强劲主要受成像一次性产品分部所得收入上升28.6%所带动。呼吸产品分部的收入回 复增长，幅度更足以抵销有余来自骨科支护复康器具分部贡献的减少。在规模经济效益扩大、营运效率 提升及存货拨备减少的因素支持下，毛利增加33.4%至159.0百万港元。毛利率由31.3%改善至35.4%。 格隆汇8月20日丨永胜医疗(01612.HK)公告，集团交出过去四年来最强劲的中期业绩，截至2025年6月30 日止6个月录得收入增长达18.1%至4.49亿港元。期间公司拥有人应占溢利增加55.1%至5160万港元。纯 利率升至12.1%(2024年上半年：8.8%)。每股盈利增加55.3%至8.03港仙(2024年上半年：5.17港仙)。贯 彻本公司的股息政策，董事会议决宣派本期间的中期股息每股2.4港仙(2024年上半年：1.6港仙)。 ...

Core Viewpoint - Yongsheng Medical (01612) reported a strong interim performance for the six months ending June 30, 2025, with significant revenue and profit growth driven by its imaging disposable products segment [1] Financial Performance - The company achieved revenue of HKD 449 million, representing an 18.05% year-on-year increase [1] - Profit attributable to owners increased by 55.1% to HKD 51.629 million [1] - Basic earnings per share were HKD 0.0803 [1] Segment Performance - Revenue from the imaging disposable products segment rose by 28.6%, significantly contributing to overall revenue growth [1] - The respiratory products segment experienced a recovery in revenue, which offset the decline from the orthopedic support rehabilitation devices segment [1] Profitability Metrics - Gross profit increased by 33.4% to HKD 159 million, supported by economies of scale, improved operational efficiency, and reduced inventory provisions [1] - Gross margin improved from 31.3% to 35.4% [1]

Core Viewpoint - Yongsheng Medical (01612) reported a strong interim performance for the six months ending June 30, 2025, with significant revenue and profit growth driven by its imaging disposable products segment [1] Financial Performance - The company achieved revenue of HKD 449 million, representing an increase of 18.05% year-on-year [1] - Profit attributable to shareholders rose to HKD 51.629 million, marking a 55.1% increase compared to the previous year [1] - Basic earnings per share were HKD 0.0803 [1] Segment Performance - Revenue from the imaging disposable products segment increased by 28.6%, contributing significantly to overall revenue growth [1] - The respiratory products segment experienced a recovery in revenue, which was sufficient to offset the decline from the orthopedic support rehabilitation devices segment [1] Profitability Metrics - Gross profit increased by 33.4% to HKD 159 million, supported by economies of scale, improved operational efficiency, and a reduction in inventory provisions [1] - Gross margin improved from 31.3% to 35.4% [1]